Table 4.
Clinical response and survival of R/R DLBCL patients treated with BTKis (N = 55).
| Total (N = 55) | Chronic HBV infection (N = 4) | Resolved HBV infection (N = 26) | No HBV infection(N = 25) | P-value | |
|---|---|---|---|---|---|
| Clinical response | |||||
| CR | 9 (16.4) | 1 (25) | 2 (7.7) | 6 (24) | 0.281 |
| PR | 30 (54.5) | 2 (50) | 14 (53.8) | 14 (56) | |
| SD | 11 (20.0) | 1 (25) | 8 (30.8) | 2 (8) | |
| PD | 5 (9.1) | 0(0) | 2 (7.7) | 3 (12) | |
| OS (mo; median; 95%CI) | NA | 5 (3.503-6.497) | 19 (NA) | NA | 0.503 |
| PFS (mo; median; 95%CI) | 4 (3-5) | 4 (1-7) | 4 (3-5) | 4 (2-6) | 0.976 |
Data are presented as n (%) of patients unless indicated otherwise.
R/R DLBCL, relapsed or refractory diffuse large B-cell lymphoma; BTKis, Bruton tyrosine kinase inhibitors; HBV, hepatitis B virus; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; OS, overall survival; CI, confidence interval; mo, month; NA, not applicable; PFS, progression-free survival.